CL2007002261A1 - Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. - Google Patents

Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.

Info

Publication number
CL2007002261A1
CL2007002261A1 CL200702261A CL2007002261A CL2007002261A1 CL 2007002261 A1 CL2007002261 A1 CL 2007002261A1 CL 200702261 A CL200702261 A CL 200702261A CL 2007002261 A CL2007002261 A CL 2007002261A CL 2007002261 A1 CL2007002261 A1 CL 2007002261A1
Authority
CL
Chile
Prior art keywords
piridazina
imidazo
cancer
prevention
treatment
Prior art date
Application number
CL200702261A
Other languages
English (en)
Inventor
Sakai Shinichi Imamura Nozomu
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CL2007002261A1 publication Critical patent/CL2007002261A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
CL200702261A 2006-08-04 2007-08-03 Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. CL2007002261A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006213981 2006-08-04
JP2006331230 2006-12-07
JP2007144072 2007-05-30

Publications (1)

Publication Number Publication Date
CL2007002261A1 true CL2007002261A1 (es) 2008-05-02

Family

ID=38996616

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702261A CL2007002261A1 (es) 2006-08-04 2007-08-03 Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.

Country Status (18)

Country Link
US (4) US8044049B2 (es)
EP (1) EP2049541B1 (es)
JP (1) JP5238697B2 (es)
KR (1) KR20090047509A (es)
AR (1) AR062207A1 (es)
AU (1) AU2007279595A1 (es)
BR (1) BRPI0714665A2 (es)
CA (1) CA2659971A1 (es)
CL (1) CL2007002261A1 (es)
CO (1) CO6150183A2 (es)
CR (1) CR10607A (es)
IL (1) IL196799A0 (es)
MA (1) MA30651B1 (es)
MX (1) MX2009001349A (es)
NO (1) NO20090986L (es)
PE (1) PE20080538A1 (es)
TW (1) TW200817409A (es)
WO (1) WO2008016192A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
ES2400604T3 (es) * 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
WO2009025358A1 (ja) 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
CA2717034A1 (en) 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
CN101372475B (zh) * 2008-03-19 2012-01-04 南京工业大学 芳杂环取代的二苯脲类衍生物及其用途
WO2009128520A1 (ja) 2008-04-18 2009-10-22 塩野義製薬株式会社 Ｐ１３ｋ阻害活性を有する複素環化合物
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
CN102256964A (zh) 2008-10-02 2011-11-23 瑞斯比维特有限公司 p38MAP激酶抑制剂
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP3372605B1 (en) 2008-10-22 2021-11-03 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
EP2399921B1 (en) * 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
CA2746357A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
CN102300850A (zh) * 2008-12-24 2011-12-28 辛根塔有限公司 制备杀真菌剂的方法
WO2010092371A1 (en) 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011137155A1 (en) 2010-04-28 2011-11-03 Bristol-Myers Squibb Company Imidazopyridazinyl compounds and their uses for cancer
TR201802093T4 (tr) 2011-04-01 2018-03-21 Genentech Inc Terapötik terapilerde kullanım için akt inhibitör bileşiği ve abirateron kombinasyonu.
KR20140103925A (ko) 2011-12-09 2014-08-27 키에시 파르마슈티시 엣스. 피. 에이. 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
EP2992112B1 (en) 2013-04-22 2020-06-03 Icahn School of Medicine at Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
US9988386B2 (en) 2013-05-30 2018-06-05 Kata Pharmaceuticals, Inc. Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof
WO2015084384A1 (en) * 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN115385741A (zh) 2013-12-13 2022-11-25 欧洲化学农业有限公司 含硝化抑制剂的肥料混合物
WO2016086026A1 (en) * 2014-11-26 2016-06-02 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
EP3231427A4 (en) * 2014-12-10 2018-07-11 Senju Pharmaceutical Co., Ltd. Aqueous liquid agent
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
BR112018070304A2 (pt) 2016-04-04 2019-01-29 Loxo Oncology Inc formulações líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
BR112018073504A2 (pt) 2016-05-18 2019-03-26 Array Biopharma, Inc. processo para preparar (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazol[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida e sais da mesma
KR20190020343A (ko) 2016-06-29 2019-02-28 오리온 코포레이션 벤조디옥산 유도체 및 이의 약제학적 용도
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US11352326B2 (en) 2016-11-16 2022-06-07 The General Hospital Corporation Myeloperoxidase imaging agents
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
WO2021075477A1 (ja) * 2019-10-16 2021-04-22 国立大学法人京都大学 運動神経細胞変性阻害剤
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022192732A1 (en) * 2021-03-12 2022-09-15 Gt Molecular, Llc Multiplexed genotyping assays with a single probe using fluorescent amplitude tuning
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001333A1 (en) 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
WO1989001478A1 (en) 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JPH0820584A (ja) 1994-07-04 1996-01-23 Takeda Chem Ind Ltd イミダゾール誘導体及びその用途
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
KR100787254B1 (ko) 1999-01-22 2007-12-20 기린 홀딩스 가부시키가이샤 퀴놀린유도체 및 퀴나졸린유도체
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
SI1255752T1 (sl) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
JP3712393B2 (ja) 2000-10-20 2005-11-02 エーザイ株式会社 含窒素芳香環誘導体
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
DE602004006536T2 (de) 2003-12-31 2008-01-31 Schering-Plough Ltd. Bekämpfng von parasiten in tieren durch anwendung von imidazoä1,2-büpyridazinderivaten
AU2005301568B2 (en) * 2004-11-08 2011-06-09 Msd K.K. Novel fused imidazole derivative
CA2594325A1 (en) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited Condensed imidazole compound and use thereof
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008016131A1 (fr) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique à cycles fusionnés

Also Published As

Publication number Publication date
IL196799A0 (en) 2009-11-18
AU2007279595A2 (en) 2009-03-19
JP2009545583A (ja) 2009-12-24
US20090137595A1 (en) 2009-05-28
US20100273788A1 (en) 2010-10-28
CA2659971A1 (en) 2008-02-07
BRPI0714665A2 (pt) 2012-03-13
US8044049B2 (en) 2011-10-25
PE20080538A1 (es) 2008-06-18
MX2009001349A (es) 2009-04-17
MA30651B1 (fr) 2009-08-03
US20100168424A1 (en) 2010-07-01
WO2008016192A2 (en) 2008-02-07
CO6150183A2 (es) 2010-04-20
TW200817409A (en) 2008-04-16
US20090306374A1 (en) 2009-12-10
US8034812B2 (en) 2011-10-11
EP2049541B1 (en) 2015-09-23
NO20090986L (no) 2009-05-04
KR20090047509A (ko) 2009-05-12
AR062207A1 (es) 2008-10-22
CR10607A (es) 2009-03-12
WO2008016192A3 (en) 2008-05-08
EP2049541A2 (en) 2009-04-22
US8273741B2 (en) 2012-09-25
JP5238697B2 (ja) 2013-07-17
AU2007279595A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
CL2008001122A1 (es) Compuestos derivados de imidazo[1,2,3-ij]-1,8-naftiridin-4,9-diona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de infecciones bacterianas.
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003155A1 (es) Compuestos derivados de 3,7-diazabiciclo[3.3.0]octano o 3,7-diazabiciclo[3.3.1]nonano, moduladores de receptores nicotinicos neuronales; composicion farmaceutica; y uso en el tratamiento de trastornos del snc.
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
CL2008000751A1 (es) Compuestos derivados de cicloprop[d]indolo[2,1-a][2]benzacepina sustituidos con heterociclos; composicion farmaceutica; y uso en el tratamiento de infeccion por hepatitis c.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
CL2007002733A1 (es) Compuestos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de obtencion de los compuestos; composicion farmaceutica; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, osteoporosis y cancer.